Clinical study on Autism with Siddha drug Maantha Nei(Internal) and Sanni Naayaga Thailam (External)

Phase-II Clinical study on Maantha Sanni (Autism Spectrum Disorder) in children with the evaluation Of Siddha trial drug Maantha Nei (Internal) and Sanni Naayaga Thailam (External) - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/108315

Enrollment

Registered

2026-04-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F988- Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence

Interventions

Intervention1: Maantha Nei(Internal) Sanni Naayaga Thailam (External): Maantha Nei for 2 to 5 years (2ml to 4ml) 5 to 8 years (4ml to 6 ml) 8 to 12 years (6ml to 7.5ml) twice a day for 48 days. Sanni

Eligibility

Inclusion criteria

Inclusion criteria: Children have lack of eye contact Lack of response Repetitive or restricted behaviour Unawareness of natural urges Acquired speech and lost it Unusual sensitive to sensory stimuli

Exclusion criteria

Exclusion criteria: Children above 12 years and below 2 years Severe and recurrent Seizures ADHD Cerebral palsy Infantile hemiplegia Congenital anomalies

Design outcomes

Primary

Measure	Time frame
Outcome is assessed by reduction of the clinical symptoms and comparing the clinical assessment parameters before and after treatment.Timepoint: 48 days	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr C Shanmuga Priya

Government Siddha Medical College, Arumbakkam, Chennai.

cspriya1974@gmail.com9445661808

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026